SHELTON, Conn., April 18, 2016 /PRNewswire/
-- NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company")
announced today that it has been recognized as one of the "Most
Innovative Business Leaders of 2016" by AI Global Media, publisher
of Acquisition International Magazine and Website ("AI")
(http://www.acquisition-intl.com).
A focus article on NanoViricides was published in AI Magazine,
February 2016 issue.
"A nanoviricide® is a nanomedicine designed to neutralize and
potentially destroy the virus. We had a chance to catch up with
representatives from the Company and learn how they are leading the
way with their advancements in this demanding field," state the
editors. The article then recites from an interview with Dr. Anil
R. Diwan, President of NanoViricides, Inc.
"NanoViricides, Inc. is a unique company in the bio/pharma field
with the potential to become a stand-alone pharmaceutical company.
We now have a fully customizable c-GMP-capable pilot manufacturing
plant where we can produce multi-kilogram quantities of any
nanoviricide, including injectables. This enables rapid translation
of our drug candidates into human clinical trials. Early revenues
upon drug approval will also be possible with our own manufacturing
capability," said Dr. Diwan, regarding the positioning of
NanoViricides in the pharma space.
"We believe that we will be transitioning our drug candidates
into clinical stage in the very near future. Our pipeline is very
broad and rich. So we will be able to advance a number of drugs
into clinical trials, one after another, in the near future,
limited only by the available finances. We believe that the chances
of clinical success of our drug candidates are very high. Thus we
anticipate advancing a number of highly effective and safe
antiviral drugs in the market, in a sustained manner. With our
advanced R&D, we believe that we will remain an innovative and
dynamic company, with continuing commercialization even after the
first drug goes to market, for a very long time into the future.
While we believe we will be able to grow organically to become a
successful stand alone pharma company, we plan to seek
commercialization options like licensing, joint ventures, and
others to improve speed to market, in order to speed up revenue,"
explained Dr. Diwan, about the future and the strategy of the
Company.
The entire AI article on NanoViricides is now available on the
NanoViricides website (www.nanoviricides.com).
AI is a monthly magazine that seeks to inform, entertain,
influence, and shape the global corporate conversation through a
combination of high quality editorial, rigorous research and an
experienced and dedicated worldwide network of advisors, experts
and contributors. Launched over five years ago, AI has
rapidly risen to become the publication of choice for more
than 108,000 subscribers in over 170 countries and regularly
attracts editorial submissions from some of the biggest
players on the global corporate landscape, including KPMG, EY,
PwC and Deloitte. Alongside the monthly publication, AI
Global Media also produces a website that is updated daily with the
latest news, features, opinion and comment, again in conjunction
with a host of top-level advisors, experts and businesspeople. The
site is also home to the popular Deal Diary, which publishes, every
day, more than 100 deals in a wide variety of sectors and
industries, and a dedicated weekly deal round-up, giving the
people behind the most significant M&A activity a
global platform to shout about their most recent
successes.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development
stage company that is creating special purpose nanomaterials for
antiviral therapy. The Company's novel nanoviricide® class of drug
candidates are designed to specifically attack enveloped virus
particles and to dismantle them. The Company is developing drugs
against a number of viral diseases including H1N1 swine flu, H5N1
bird flu, seasonal Influenza, HIV, oral and genital Herpes, viral
diseases of the eye including EKC and herpes keratitis, Hepatitis
C, Rabies, Dengue fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are "forward-looking statements" within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
which are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities.
Although it is not possible to predict or identify all such
factors, they may include the following: demonstration and proof of
principle in pre-clinical trials that a nanoviricide is safe and
effective; successful development of our product candidates; our
ability to seek and obtain regulatory approvals, including with
respect to the indications we are seeking; the successful
commercialization of our product candidates; and market acceptance
of our products.
Photo -
http://photos.prnewswire.com/prnh/20150107/167444LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanoviricides-inc-recognized-as-one-of-the-most-innovative-businesses-2016-by-ai-global-media---acquisitions-international-300252732.html
SOURCE NanoViricides, Inc.